Which GLP-1 medicines are approved for what
GLP-1 receptor agonists are a drug class, not a single product. Semaglutide, tirzepatide, and liraglutide are different molecules with different brands, and tirzepatide is a dual GIP and GLP-1 receptor agonist rather than a GLP-1 agonist alone. NIDDK’s patient table makes the practical split: Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide) are the names it lists for weight management, while Victoza, Ozempic, Rybelsus, and Mounjaro are the diabetes names of related products. Using one brand name for all of them hides indications. This entry is the map. Dose tables are in the semaglutide, tirzepatide, and liraglutide entries. Oral products and compounded copies are in oral and compounded.
Semaglutide products are not one label
Wegovy (semaglutide) injection is indicated, with diet and activity, for three clusters of uses on the current DailyMed label. One is reduction of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. One is long-term weight reduction in adults and in pediatric patients 12 years and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition. One is noncirrhotic MASH with moderate to advanced fibrosis, under accelerated approval, meaning continued approval can depend on a confirmatory trial. Wegovy tablets are indicated in adults for the cardiovascular risk-reduction use and for long-term weight reduction in obesity or in overweight with a weight-related condition. The label says not to use the tablets or the injection together with other semaglutide-containing products or any other GLP-1 receptor agonist. Drugs@FDA application 215256 is the injection’s approval history. Tablet labeling is inside the same DailyMed record reviewed for this entry.
Ozempic injection is semaglutide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, to reduce major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Its labeled weekly doses run 0.25 mg to start, then 0.5 mg, with further increases to 1 mg and 2 mg when more glucose control is needed. Those milligrams are not Wegovy’s weight-management schedule.
Rybelsus and the Ozempic tablet described on the same DailyMed record are oral semaglutide indicated for glycemic control in adults with type 2 diabetes and for cardiovascular risk reduction in adults with type 2 diabetes at high risk. The record says the tablet products are not substitutable on a milligram-for-milligram basis. Rybelsus dosing in that record starts at 3 mg daily for 30 days, a dose the label says is not effective for glycemic control, then 7 mg, then 14 mg if more control is needed. That is not the Wegovy tablet schedule of 1.5 mg, 4 mg, 9 mg, and 25 mg.
Tirzepatide products
Zepbound (tirzepatide) is indicated with diet and activity to reduce excess body weight and maintain weight reduction in adults with obesity or with overweight plus at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity. The label says not to combine it with other tirzepatide-containing products or any GLP-1 receptor agonist. Maintenance for weight reduction is 5, 10, or 15 mg weekly. Maintenance for obstructive sleep apnea is 10 or 15 mg. The 2.5 mg dose is initiation only.
Mounjaro (tirzepatide) is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes, and, on the DailyMed record reviewed for this entry, to reduce major adverse cardiovascular events in adults with type 2 diabetes at high risk. The starting dose is 2.5 mg weekly. The adult maximum on that record is 15 mg weekly. The pediatric maximum for the diabetes indication is 10 mg weekly. A weight-loss page that tells a 12-year-old’s family to “use Mounjaro like Zepbound” is crossing indications and age ranges the labels do not treat as the same.
Liraglutide products
Saxenda (liraglutide) is indicated with diet and activity for long-term weight reduction in adults and in pediatric patients 12 and older who weigh more than 60 kg and have obesity, and in adults with overweight plus at least one weight-related condition. The recommended adult dose is 3 mg daily. Coadministration with other liraglutide-containing products or any other GLP-1 receptor agonist is not recommended. Victoza is the diabetes liraglutide product NIDDK points to, at a lower dose. This reference does not treat Victoza’s diabetes dose as a weight-management dose. See the liraglutide entry before assuming a daily pen is Saxenda.
Shared warnings that are not shared indications
Wegovy, Zepbound, and Saxenda each carry a boxed warning about thyroid C-cell tumors in rodents and a contraindication in people with a personal or family history of medullary thyroid carcinoma or with MEN 2. Each warns about pancreatitis, gallbladder disease, gastrointestinal adverse reactions that can be severe, and hypoglycemia when combined with insulin or an insulin secretagogue. Pregnancy language says the drugs may cause fetal harm. Those shared warnings do not mean the drugs are interchangeable. Average weight change in STEP 1 (semaglutide 2.4 mg, −14.9 percent at 68 weeks versus −2.4 percent with placebo) and in SURMOUNT-1 (tirzepatide −15.0, −19.5, and −20.9 percent at 72 weeks for 5, 10, and 15 mg versus −3.1 percent with placebo) came from different molecules, doses, and protocols. The labels forbid comparing adverse-reaction rates across those programs as if the trials had been one experiment.
Who the weight-management indications describe, in ordinary language, is discussed for patients on a separate eligibility guide. That guide is not a second label. If it and this entry ever diverge, the prescribing information wins, and this entry should be corrected.
What this map leaves out on purpose
It does not list every GLP-1 receptor agonist ever approved for diabetes, such as dulaglutide, because this reference is organized around the products people currently confuse in weight-loss searches. It does not assign a winner. It does not describe pipeline drugs as approved. A CMS demonstration page has named an additional product, Foundayo, among drugs in a Medicare GLP-1 Bridge. This entry does not restate Foundayo’s indication or dose, because a CMS list is not a substitute for reading that product’s label, and this review did not rely on a label monograph for it. If you were handed a product that does not appear in the table below, ask the pharmacist to match the name to a DailyMed record before you inject it.
| Brand on the box | Active ingredient | Role of the indication this entry relies on |
|---|---|---|
| Wegovy injection | semaglutide | Weight reduction, cardiovascular risk reduction, accelerated-approval MASH |
| Wegovy tablets | semaglutide | Adult weight reduction and cardiovascular risk reduction |
| Ozempic injection | semaglutide | Type 2 diabetes glycemic control, cardiovascular risk, kidney risk |
| Rybelsus / Ozempic tablets | semaglutide | Type 2 diabetes glycemic control and cardiovascular risk |
| Zepbound | tirzepatide | Adult weight reduction and obstructive sleep apnea in adults with obesity |
| Mounjaro | tirzepatide | Type 2 diabetes glycemic control, including some pediatric use, and cardiovascular risk in adults on the record reviewed |
| Saxenda | liraglutide | Weight reduction in specified adults and adolescents |
The rows are a finding aid. They are not dosing instructions. Open the monograph that matches the molecule before you compare pens.
Label and trial list
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42bdd912-2393-44c4-b7e0-47672ca28991
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s041lbl.pdf
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/206321s024lbl.pdf
- https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256